Ibio Inc (IBIO)
$2.46 0.11 (4.68%)
20:00 EDT IBIO Stock Quote Delayed 30 Minutes
Previous Close $2.42
Market Cap 39.22M
PE Ratio -1.45
Volume (Avg. Vol.) 19.81M
Day's Range 2.22 - 2.46
52-Week Range 0.05 - 7.45
Dividend & Yield N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
- From InvestorPlace
- From the Web
IBIO stock isn't the coronavirus vaccine bet investors should pursue, with its candidates in pre-clinical stages showing minimal promise.
iBio stock offers investors an exciting speculative bet. It already showed its potential this year so it could have repeat performance soon.
By Ian Cooper
At the moment, it’s better to just avoid iBio stock. There are far better opportunities to be found in this market.
There has been a lot of noise surrounding IBIO stock. But investors need that noise to turn into actionable news to reverse the stock's trend.
A few months ago, there was lots of optimism for IBIO stock. But unfortunately, the company has not been able to live up to the lofty expectations.
One of the earlier Covid-19 darlings, IBIO stock has shed much of its enthusiasm. However, recent news could move the needle again.
Ibio recently announced IBIO-201 as its coronavirus vaccine candidate. Despite a long road ahead, it’s good news for IBIO stock.
If you've been waiting for a catalyst to buy beaten-down IBIO stock, a worldwide licensing deal should convince you to take action.
iBio has had a thrilling 2020. But with its Covid-19 products far from approval, and others ahead, IBIO stock is set for a slump.
IBIO stock is delivering heartache and more could be on the way as markets realize the company isn't going to deliver a Covid-19 vaccine.
iBio's leading vaccine and its therapy appear to be too far behind the competition to generate much revenue for IBIO stock.
Sure, iBio hopes to win the Covid-19 vaccine race, but right now, IBIO stock investors aren't benefiting from the pursuit.
Markets realize that the biotech firm is not close to delivering a vaccine, and IBIO stock is getting punished as a result.
IBIO stock is a speculative play due to the slow development of its pipeline and its lack of much support from external parties.
Both the potential rewards and risks offered by IBIO stock are high. But for Covid-19 vaccine bets, there are better options for investors.
By Thomas Niel
So, what's the play here? Too risky to go long (or short), stay far away vaccine play IBIO stock. Other vaccine candidates may offer opportunity. But, this "also-ran" isn't much of a contender.
iBio stock ripper higher by 30% on Aug 24. Is it time to buy the stock now? Technically, it would be better to see a little more strength.
iBio is behind others in developing a Covid-19 vaccine and it doesn't have a FastPharming partner. There's diminishing value to IBIO stock.
Lifestyle Drugs Market 2020 Analysis and Precise Outlook – Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience
From X herald
From Seeking Alpha
Amid concerns among Americans that the rush to approve COVID-19 vaccines may lead to corner-cutting and end products that are not up to typical FDA efficacy standards, leading developers Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) have taken the unusual steps of publishing the protocols of the large-scale late-stage trials for their respective candidates.Moderna's Phase 3 trial of mRNA-1273, two 100 microgram doses 28 days apart, will recruit ~30K adults, 60-75% younger than 65 years old not at risk for complications and 25-40% at least 65 years old (the single most significant risk factor) or less than 65 at increased risk of COVID-19 complications.The primary efficacy endpoint is the incidence of first-occurrence COVID-19 cases starting 14 days after the second shot.A confirmed (via molecular test) COVID-19 case is defined as a participant who has experienced at least TWO of the following symptoms: fever (≥ 38ºC), chills, myalgia (muscle soreness), headache, sore throat, new olfactory and taste disorder(s) OR he/she must have experienced at least ONE of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing OR clinical or radiographic evidence of pneumonia.Pfizer and BioNTech's (NASDAQ:BNTX) Phase 3 study of BNT162b2, two 30 microgram doses 21 days apart, will recruit 30K adults stratified in two groups: 16-55 years old and 55+.The primary efficacy endpoint is the incidence of confirmed COVID-19 cases starting 7 days after the second shot as measured by the number of cases per 1,000 person-years of follow-up.A confirmed (via molecular test) COVID-19 case is defined as participants experiencing at least ONE of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased myalgia (muscle soreness), new loss of taste or smell, sore throat, diarrhea or vomiting.Moderna's criteria are a more restrictive and could potentially show a higher efficacy rate for mRNA-1273 as a result.The number of COVID-19 cases in people who just reported one symptom is unknown.
Acute Coronary Syndrome Therapeutic Market Research Report by Type, by Drug, by Treatment, by Diagnosis, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
Navellier RatingsPowered by Portfolio Grader